Individuals with pre-bronchodilator airflow obstruction appeared to be at significant risk for future COPD development, researchers reported in the American Journal of Respiratory and Critical Care ...

Researchers have found that dual bronchodilators -- long-lasting inhalers that relax the airways and make it easier to breathe -- do little to help people who do not have chronic obstructive pulmonary ...

The IMPACT and ETHOS trials showed that single-inhaler triple therapy significantly reduce the rate of COPD exacerbation and mortality compared with dual bronchodilators. Findings are from an ...

Among 535 symptomatic smokers with a 10 pack-year history and preserved lung function assessed by spirometry, 56.4% in the treatment group and 59.0% in the placebo group had a least a 4-point decrease ...

Researchers supported by the National Institutes of Health have found that dual bronchodilators - long-lasting inhalers that relax the airways and make it easier to breathe - do little to help people ...

Current or former smokers who ha­ve clinically significant respiratory symptoms but no spirometric evidence of airway obstruction are often treated with dual bronchodilators commonly prescribed for ...

Over-the-counter (OTC) inhalers are not approved for treating chronic obstructive pulmonary disease (COPD). Aside from the fact that they are ineffective for COPD, these inhalers can pose risks ...

"In patients with risk factors for COPD and respiratory symptoms, referring for spirometry is important to triage who will and won’t benefit from bronchodilators." – Meilan Han, MD, Professor of ...

A new COPD drug, developed by Verona Pharma, was approved by the FDA Wednesday. The drug, ensifentrine, is the first new type of maintenance treatment for COPD in over a decade. In clinical trials, ...

Researchers supported by the National Institutes of Health have found that dual bronchodilators – long-lasting inhalers that relax the airways and make it easier to breathe – do little to help people ...